7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 2009-09-30 2009-06-30 2009-03-31 2008-09-30 2008-06-30 2008-03-31 2007-09-30 2007-06-30 2007-03-31 2006-12-31 2006-09-30 2006-06-30 2006-03-31 2005-12-31 2005-09-30 2005-06-30 2005-03-31 2004-12-31 2004-09-30 
      
    		                                                                         
      assets
    		                                                                         
      current assets:
    		                                                                         
      cash and cash equivalents
    		476,513,000 397,532,000 319,090,000 304,964,000 260,630,000 217,003,000 178,357,000 193,513,000 179,997,000 173,025,000 144,049,000 291,049,000 300,789,000 283,580,000 216,802,000 201,525,000 135,115,000 43,265,000 282,890,000 246,487,000 479,193,000 413,147,000 351,981,000 278,096,000 172,946,000 141,952,000 65,151,000 48,615,000 87,226,000 27,138,000 138,417,000 127,634,000 159,808,000 93,194,000 112,945,000 151,778,000 78,746,000 149,579,000 141,186,000 119,575,000 208,052,000 125,275,000 171,892,000 199,243,000 266,070,000 112,235,000 161,096,000 14,310,000 62,736,000 90,658,000 147,874,000 63,101,000 69,721,000 109,923,000 65,589,000 61,098,000 72,918,000 128,966,000 87,610,000 81,283,000 78,860,000 45,545,000 77,152,000 72,388,000 85,730,000 84,898,000 103,522,000 49,787,000 22,359,000 63,879,000 85,499,000 101,411,000 38,004,000 
      accounts receivable
    		30,167,000 20,925,000 16,673,000 20,392,000 30,546,000 26,782,000 14,139,000 14,454,000 10,752,000 15,275,000 15,490,000 9,401,000 6,743,000                             3,000 450,000                               
      receivables from collaboration arrangement
    		63,352,000 67,336,000 61,263,000  60,512,000 67,198,000 61,871,000  57,014,000 65,721,000 60,314,000  65,606,000                                                             
      inventory
    		38,363,000 48,996,000 41,479,000 33,725,000 34,236,000 36,664,000 37,437,000 40,737,000 40,515,000 46,846,000 49,653,000 55,897,000 70,807,000                                 5,148,000 4,299,000                           
      prepaid expenses
    		19,415,000 16,610,000 15,414,000 21,063,000 12,650,000 8,484,000 16,551,000 21,630,000 14,729,000 20,535,000 24,119,000 29,559,000 7,932,000 3,953,000 5,576,000                                                           
      current portion of isp fund investments
    		56,589,000 100,198,000 127,790,000 107,532,000                                                                      
      other current assets
    		171,000 181,000 313,000 656,000 2,047,000 2,146,000 2,987,000 4,264,000 1,992,000 2,136,000 2,821,000 2,933,000 2,432,000 1,119,000 1,930,000                                                           
      total current assets
    		684,570,000 651,778,000 582,022,000 554,306,000 400,621,000 358,277,000 311,342,000 344,219,000 304,999,000 323,538,000 296,446,000 443,511,000 454,591,000 400,328,000 317,823,000 313,673,000 236,928,000 148,261,000 372,933,000 342,058,000 572,041,000 500,193,000 466,907,000 431,234,000 366,795,000 317,685,000 251,519,000 121,129,000 178,660,000 113,245,000 220,509,000 198,064,000 214,418,000 186,121,000 190,421,000 196,706,000 223,754,000 243,957,000 262,392,000 273,471,000 353,163,000 389,196,000 522,341,000 457,233,000 474,512,000 282,535,000 303,380,000 204,327,000 269,165,000 288,625,000 300,272,000 197,487,000 216,223,000 232,149,000 162,870,000 184,473,000 189,900,000 227,727,000 252,491,000 268,380,000 144,436,000 156,926,000 190,685,000 207,167,000 227,385,000 247,507,000 266,916,000 166,818,000 177,011,000 213,248,000 238,506,000 264,468,000 182,291,000 
      property and equipment
    		1,529,000 451,000 483,000 514,000 544,000 427,000 324,000 483,000 361,000 161,000 180,000 170,000 165,000 176,000 191,000 12,000 15,000 19,000 24,000 28,000 33,000 37,000 42,000 33,000 24,000 136,000 148,000 173,000 185,000 197,000 249,000 289,000 328,000 381,000 174,000 193,000 248,000 276,000 303,000 64,000  9,734,000 8,563,000 8,952,000 9,010,000 9,579,000 9,660,000 10,059,000 10,206,000 10,334,000 10,548,000 10,253,000 11,049,000 11,881,000 13,910,000 14,712,000 15,233,000 17,328,000 18,481,000 19,480,000 19,847,000 18,698,000 16,183,000 15,101,000 14,281,000 13,413,000 13,419,000 13,180,000 13,062,000 13,631,000 13,395,000 13,242,000 13,831,000 
      equity method investments
    		82,577,000 51,826,000 38,744,000 52,293,000 73,549,000 91,780,000 151,888,000 116,546,000 107,040,000 35,061,000 54,971,000                                                               
      equity and long-term investments
    		343,794,000 297,284,000 291,100,000 341,664,000 434,169,000 444,655,000 476,549,000 444,432,000 422,491,000 397,940,000 400,894,000 403,013,000 489,111,000 494,097,000 544,437,000 483,845,000 507,116,000                                                         
      capitalized fees paid
    		59,593,000 63,049,000 66,505,000 69,961,000 73,416,000 76,872,000 80,328,000 83,784,000 87,239,000 90,695,000 94,151,000 97,607,000                                                              
      right-of-use assets
    		1,402,000 1,759,000 2,110,000 2,453,000 2,789,000 3,118,000 2,269,000 2,536,000 2,828,000 2,719,000 2,973,000 3,265,000 3,679,000 3,545,000 3,794,000                                                           
      goodwill
    		17,905,000 17,905,000 17,905,000 17,905,000 17,905,000 17,905,000 17,905,000 17,905,000 17,905,000 14,882,000 27,946,000 26,713,000 15,995,000 5,544,000 5,544,000                                                           
      intangible assets
    		188,793,000 195,411,000 201,958,000 208,433,000 210,944,000 217,455,000 223,895,000 230,335,000 236,845,000 243,356,000 248,314,000 252,919,000 258,489,000 105,000,000 105,000,000                         211,646,000 194,880,000 137,477,000 40,000,000                               
      deferred tax assets
    		7,982,000 12,931,000 12,294,000 12,054,000 14,875,000 11,446,000   4,952,000 6,327,000    23,274,000 22,398,000 17,327,000 28,159,000          187,546,000                                               
      other assets
    		40,961,000 41,178,000 41,269,000 41,477,000 2,800,000 2,982,000 3,112,000 3,267,000 3,444,000 3,562,000 3,893,000 4,299,000 4,620,000 1,157,000 313,000 108,000 136,000 162,000 188,000 214,000 239,000 264,000 288,000 312,000 48,000 37,000 37,000 37,000 37,000 37,000 37,000 37,000 37,000 40,000 58,000 18,000 15,805,000 16,574,000 17,337,000 19,947,000 22,385,000 7,963,000 5,946,000      2,721,000 2,928,000 3,135,000             24,000 100,000 99,000 97,000 100,000 106,000 30,000 31,000 177,000 246,000 
      total assets
    		1,429,106,000 1,333,572,000 1,254,390,000 1,301,060,000 1,231,612,000 1,224,917,000 1,267,612,000 1,243,507,000 1,188,104,000 1,118,241,000 1,129,768,000 1,231,497,000 1,327,712,000 1,137,639,000 1,107,474,000 926,395,000 887,239,000 789,150,000 1,088,290,000 999,570,000 922,256,000 879,619,000 788,011,000 724,826,000 675,953,000 642,307,000 590,114,000 277,693,000 338,692,000 276,745,000 390,972,000 372,023,000 391,872,000 370,542,000 378,109,000 387,829,000 437,631,000 462,086,000 488,699,000 553,713,000 605,610,000 605,034,000 666,016,000 594,704,000 591,519,000 383,943,000 399,422,000 217,727,000 283,325,000 303,120,000 315,108,000 212,580,000 232,449,000 249,930,000 183,472,000 206,085,000 214,792,000 255,262,000 281,390,000 299,515,000 198,623,000 208,008,000 247,659,000 262,424,000 292,350,000 318,897,000 327,334,000 224,835,000 196,988,000 233,801,000 259,196,000 286,022,000 204,974,000 
      liabilities and stockholders’ equity
    		                                                                         
      current liabilities:
    		                                                                         
      accounts payable
    		6,243,000 5,382,000 4,700,000 2,132,000 4,170,000 2,039,000 890,000 6,717,000 3,783,000 4,592,000 5,933,000 2,939,000 3,805,000 4,323,000 1,808,000 27,000 89,000 30,000 14,000 66,000 623,000 195,000 122,000 10,000 35,000 1,139,000 144,000 109,000 58,000 66,000 629,000 277,000 2,304,000 528,000 137,000 576,000 154,000 462,000 1,025,000 573,000 1,799,000 5,546,000 5,733,000 4,834,000 3,525,000 4,757,000 4,989,000 5,308,000 3,699,000 2,165,000 2,214,000 1,776,000 1,749,000 1,999,000 1,046,000 1,823,000 1,991,000 2,527,000 3,068,000 4,699,000 5,954,000 7,892,000 8,818,000 16,011,000 8,075,000 10,493,000 11,429,000 8,118,000 7,781,000 8,199,000 9,882,000 5,925,000 3,809,000 
      accrued personnel-related expenses
    		6,819,000 4,750,000 3,789,000 7,376,000 5,965,000 4,757,000 3,422,000 7,020,000 5,166,000 5,474,000 4,223,000 8,022,000 6,473,000 3,871,000 1,933,000 619,000 488,000 389,000 652,000 490,000 384,000 291,000 274,000 647,000 509,000 371,000 325,000 1,550,000 695,000 537,000 1,647,000 1,203,000 998,000 1,625,000 1,126,000 913,000 1,392,000 1,003,000 1,063,000 1,203,000 1,023,000 13,829,000 8,362,000 6,001,000 5,128,000 7,714,000   7,123,000 5,154,000  6,398,000 4,692,000 4,133,000 9,482,000 7,958,000 7,552,000 9,116,000 9,898,000 9,783,000 10,597,000 9,263,000 6,154,000 8,316,000 6,562,000 4,423,000 3,950,000 6,041,000 7,828,000 7,092,000 5,149,000 7,615,000 5,793,000 
      accrued interest payable
    		231,000 3,418,000 833,000 3,422,000 833,000 3,422,000 833,000 3,422,000 833,000 3,422,000 833,000 4,359,000 5,702,000 4,498,000 1,397,000 4,152,000 1,668,000 4,152,000 1,668,000 4,152,000 1,668,000 4,152,000 1,668,000 4,152,000 1,773,000 4,262,000 1,775,000 1,775,000 5,115,000 2,545,000 3,566,000 7,103,000 6,400,000 6,606,000 7,823,000 6,562,000 6,390,000 7,925,000 6,195,000 19,467,000 11,013,000                                 
      deferred revenue
    		13,571,000 3,125,000 1,002,000 1,126,000 717,000 855,000 987,000 1,277,000 1,548,000 3,254,000 2,094,000 2,094,000 2,849,000                  1,551,000 1,772,000 1,993,000 885,000 885,000 885,000 885,000 885,000 885,000 1,082,000 1,082,000 5,247,000        127,393,000 132,409,000 142,246,000 147,946,000 153,647,000 144,946,000 150,495,000 146,792,000 158,510,000 164,509,000 161,421,000 171,544,000 153,733,000 159,038,000 134,383,000 136,555,000 132,660,000 110,467,000 111,251,000 54,601,000 57,607,000 57,978,000 56,339,000 59,079,000 
      convertible subordinated notes due 2025, net of issuance costs
    		 191,903,000 192,215,000  191,843,000                                                                     
      other accrued liabilities
    		21,607,000 37,985,000 30,664,000 29,999,000 17,599,000 17,133,000 23,747,000 19,698,000 24,699,000 22,502,000 24,900,000 21,207,000 15,120,000 17,144,000 8,073,000 1,009,000 880,000 800,000 1,470,000 1,402,000 1,223,000 776,000 734,000 562,000 1,012,000 1,386,000 1,258,000 865,000 909,000 918,000 1,157,000 2,460,000 3,183,000 1,729,000 1,392,000 1,687,000 2,457,000 1,789,000 1,686,000 3,773,000 4,834,000 4,792,000 3,093,000 4,703,000 2,678,000 1,835,000 2,077,000 1,974,000    2,650,000 4,335,000 4,003,000 3,986,000 5,470,000 3,754,000 3,072,000 6,483,000 4,104,000 2,795,000 3,431,000 3,519,000 2,314,000 2,000,000 1,653,000 2,208,000 1,997,000 1,966,000 2,213,000 2,094,000 2,338,000 4,573,000 
      total current liabilities
    		48,471,000 246,563,000 234,745,000 236,083,000 223,750,000 28,206,000 29,879,000 38,134,000 36,183,000 39,398,000 38,137,000 134,968,000 163,884,000 125,908,000 109,227,000 5,807,000 3,125,000 5,371,000 3,804,000 6,110,000 3,898,000 5,414,000 2,798,000 5,371,000 3,329,000 7,475,000 3,810,000 4,299,000 6,777,000 4,066,000 32,884,000 27,109,000 20,473,000 14,924,000 14,629,000 10,623,000 11,278,000 12,214,000 10,980,000 36,098,000 49,994,000 44,144,000 38,661,000 38,646,000 29,464,000 27,090,000 25,776,000 25,575,000 39,814,000 35,191,000 33,419,000 36,381,000 36,004,000 35,576,000 39,341,000 40,369,000 37,416,000 43,705,000 50,172,000 49,720,000 57,136,000 59,802,000 62,886,000 59,609,000 54,801,000 54,047,000 53,112,000 48,173,000 40,427,000 38,330,000 36,013,000 35,037,000 33,311,000 
      long-term debt, net of discount and issuance costs
    		257,377,000 257,019,000 256,670,000 256,316,000 255,972,000 447,282,000 446,759,000 446,234,000 445,718,000 445,201,000 444,692,000 444,180,000 443,679,000 443,178,000 442,731,000 394,653,000 392,295,000 389,989,000 387,728,000 385,517,000 383,350,000 381,230,000 379,152,000 377,120,000 388,644,000 386,675,000 384,744,000                                               
      other long-term liabilities
    		57,431,000 60,021,000 62,009,000 64,275,000 71,449,000 72,065,000 71,686,000 71,870,000 68,690,000 68,584,000 70,133,000 70,918,000 78,421,000    14,000     163,000 192,000  217,000 298,000 379,000 668,000 752,000 835,000 1,049,000 1,159,000 1,267,000 1,598,000 1,639,000 1,784,000 1,847,000 1,748,000 1,947,000 1,530,000 1,300,000             314,000 466,000 543,000 620,000 3,670,000 3,655,000               
      income tax payable, long-term
    		55,876,000 55,148,000 54,061,000 53,227,000 11,899,000 11,849,000 11,800,000 11,751,000 10,020,000 9,971,000 9,921,000 9,872,000                                                              
      commitments and contingencies
    		                                                                         
      stockholders’ equity:
    		                                                                         
      preferred stock: 0.01 par value, 230 shares authorized, no shares issued and outstanding
    		                                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 74,769 and 62,665 issued and outstanding as of september 30, 2025 and december 31, 2024, respectively
    		748,000                                                                         
      additional paid-in capital
    		903,988,000 698,884,000 694,658,000 692,329,000 690,045,000 688,231,000 1,085,539,000 1,093,340,000 1,107,398,000 1,117,029,000 1,124,709,000 1,163,836,000 1,171,096,000 1,183,667,000 1,182,912,000 1,264,024,000 1,262,438,000 1,261,845,000 1,261,326,000 1,260,900,000 1,260,447,000 1,260,017,000 1,259,464,000 1,258,859,000 1,258,370,000 1,257,799,000 1,257,125,000 1,258,350,000 1,259,443,000 1,257,880,000 1,336,358,000 1,286,340,000 1,284,031,000 1,292,655,000 1,312,434,000 1,328,155,000 1,375,805,000 1,400,253,000 1,426,297,000 1,466,911,000 1,444,105,000 1,834,862,000 1,784,016,000 1,492,945,000 1,462,288,000 1,475,371,000 1,456,882,000 1,236,641,000 1,218,934,000 1,210,006,000 1,194,620,000 1,039,357,000 1,033,427,000 1,025,548,000 918,634,000 912,070,000 905,453,000 889,844,000 882,369,000 876,007,000 863,177,000 855,951,000 846,924,000 840,498,000 833,452,000 827,704,000 818,160,000 676,299,000 674,109,000 673,969,000 671,144,000 669,698,000 562,355,000 
      retained earnings
    		105,215,000 15,307,000     11,343,000                                                                   
      total stockholders’ equity
    		1,009,951,000 714,821,000 646,905,000 691,159,000 668,542,000 665,515,000 703,681,000 674,955,000 627,493,000 555,087,000 561,493,000 565,788,000 641,368,000 565,462,000 552,217,000 525,935,000 491,805,000 393,745,000 696,681,000 607,837,000 534,872,000 492,812,000 405,869,000 342,116,000 283,763,000 246,702,000 199,943,000               263,252,000 330,049,000 85,647,000 91,511,000 173,288,000 189,256,000 6,131,000               20,344,000 63,310,000 94,034,000 125,607,000 157,520,000 59,584,000 98,177,000 133,958,000 161,078,000 190,367,000 108,098,000 
      total liabilities and stockholders’ equity
    		1,429,106,000 1,333,572,000 1,254,390,000 1,301,060,000 1,231,612,000 1,224,917,000 1,267,612,000 1,243,507,000 1,188,104,000 1,118,241,000 1,129,768,000 1,231,497,000 1,327,712,000 1,137,639,000 1,107,474,000 926,395,000 887,239,000 789,150,000 1,088,290,000 999,570,000 922,256,000 879,619,000 788,011,000 724,826,000 675,953,000 642,307,000 590,114,000              605,610,000 605,034,000 666,016,000 594,704,000 591,519,000 383,943,000 399,422,000 217,727,000          255,262,000 281,390,000 299,515,000 198,623,000 208,008,000 247,659,000 262,424,000 292,350,000 318,897,000 327,334,000 224,835,000 196,988,000 233,801,000 259,196,000   
      common stock: 0.01 par value, 200,000 shares authorized, 63,011 and 62,665 issued and outstanding as of june 30, 2025 and december 31, 2024, respectively
    		 630,000                                                                        
      income tax payable
    		  1,542,000  2,623,000    154,000 154,000 154,000 154,000 33,804,000                                                             
      common stock: 0.01 par value, 200,000 shares authorized, 62,771 and 62,665 issued and outstanding as of march 31, 2025 and december 31, 2024, respectively
    		  628,000                                                                       
      accumulated deficit
    		  -48,381,000 -1,797,000 -22,129,000 -23,342,000  -25,189,000 -86,720,000 -168,766,000 -170,046,000 -204,911,000 -136,597,000 -402,198,000 -403,137,000 -456,148,000 -466,493,000 -538,931,000 -627,879,000 -722,002,000 -775,905,000 -804,123,000 -880,967,000 -946,404,000 -992,353,000 -1,032,162,000                                                
      receivable from collaboration arrangements
    		   65,974,000                                         2,217,000                             
      convertible notes, due 2025, net of issuance costs
    		   192,028,000                                                                      
      deferred tax liabilities
    		      3,807,000 563,000   5,392,000 5,771,000 360,000                                                             
      common stock: 0.01 par value, 200,000 shares authorized, 62,665 and 63,307 issued and outstanding as of december 31, 2024 and 2023 respectively
    		   627,000                                                                      
      treasury stock
    		      -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000 -393,829,000                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 62,601 and 63,307 issued and outstanding as of september 30, 2024 and december 31, 2023, respectively
    		    626,000                                                                     
      common stock: 0.01 par value, 200,000 shares authorized, 62,562 and 63,307 issued and outstanding as of june 30, 2024 and december 31, 2023, respectively
    		     626,000                                                                    
      common stock: 0.01 par value, 200,000 shares authorized, 62,797 and 63,307 issued and outstanding as of march 31, 2024 and december 31, 2023, respectively
    		      628,000                                                                   
      receivables from collaboration arrangements
    		       69,621,000    54,672,000                                                              
      convertible subordinated notes due 2023, net of issuance costs
    		           96,193,000 96,131,000 96,072,000 96,016,000                                                           
      common stock: 0.01 par value, 200,000 shares authorized, 63,307 and 69,188 issued and outstanding as of december 31, 2023 and december 31, 2022 respectively
    		       633,000                                                                  
      common stock: 0.01 par value, 200,000 shares authorized, 64,384 and 69,188 issued and outstanding as of september 30, 2023 and december 31, 2022, respectively
    		        644,000                                                                 
      common stock: 0.01 par value, 200,000 shares authorized, 65,225 and 69,188 issued and outstanding as of june 30, 2023 and december 31, 2022, respectively
    		         653,000                                                                
      common stock: 0.01 par value, 200,000 shares authorized, 65,824 and 69,188 issued and outstanding as of march 31, 2023 and december 31, 2022, respectively
    		          659,000                                                               
      common stock: 0.01 par value, 200,000 shares authorized, 69,188 and 69,566 issued and outstanding as of december 31, 2022 and december 31, 2021 respectively
    		           692,000                                                              
      total innoviva stockholders’ equity
    		           565,788,000 641,368,000 388,337,000 386,642,000 414,743,000 402,811,000          188,245,000                                               
      noncontrolling interests
    		                                                                         
      short-term marketable securities
    		            282,000         3,999,000 31,970,000 72,749,000 124,255,000 107,711,000 127,027,000 6,865,000 20,316,000 29,322,000 29,775,000 7,992,000 10,003,000 55,772,000 40,921,000 16,414,000 127,446,000 79,684,000 109,954,000 143,536,000                                  
      capitalized fees paid to a related party
    		            101,062,000 104,518,000 107,974,000 111,430,000 114,885,000 118,341,000 121,797,000 125,253,000 128,708,000 132,164,000 135,620,000 139,076,000 142,531,000 145,987,000 149,443,000 156,354,000 159,810,000 163,266,000 170,177,000 173,633,000 177,089,000 184,000,000 187,456,000 190,912,000 197,824,000 201,279,000                                    
      common stock: 0.01 par value, 200,000 shares authorized, 69,776 and 69,566 issued and outstanding as of september 30, 2022 and december 31, 2021 respectively
    		            698,000                                                             
      noncontrolling interest
    		             177,125,000 165,575,000 111,192,000 88,994,000          11,698,000 3,081,000 1,992,000 811,000                                            
      related party receivables from collaborative arrangements
    		             111,676,000 93,515,000 110,711,000 101,271,000 104,262,000 88,974,000 93,931,000 92,150,000 82,402,000 82,134,000 79,427,000 69,211,000 67,563,000 58,639,000 65,136,000 70,542,000 55,835,000 51,878,000 61,796,000 43,727,000 36,621,000 35,817,000 27,539,000 16,947,000 13,997,000 10,239,000                                   
      lease liabilities, long-term
    		             3,091,000 3,299,000                                                           
      common stock: 0.01 par value, 200,000 shares authorized, 69,706 and 69,566 issued and outstanding as of june 30, 2022 and december 31, 2021 respectively
    		             697,000                                                            
      common stock: 0.01 par value, 200,000 shares authorized, 69,594 and 69,566 issued and outstanding as of march 31, 2022 and december 31, 2021 respectively
    		              696,000                                                           
      prepaid expenses and other current assets
    		               1,437,000 542,000 734,000 1,069,000 1,640,000 698,000 645,000 822,000 962,000 383,000 459,000 702,000 513,000 576,000 950,000 439,000 642,000 880,000 534,000 738,000 975,000 615,000 697,000 1,013,000 748,000 982,000 6,391,000 4,071,000 3,609,000 5,190,000    3,848,000 4,506,000 5,751,000                       
      common stock: 0.01 par value, 200,000 shares authorized, 69,566 and 101,392 issued and outstanding as of december 31, 2021 and december 31, 2020 respectively
    		               696,000                                                          
      common stock: 0.01 par value, 200,000 shares authorized, 69,492 and 101,392 issued and outstanding as of september 30, 2021 and december 31, 2020 respectively
    		                695,000                                                         
      ​
    		                                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 69,495 and 101,392 issued and outstanding as of june 30, 2021 and december 31, 2020, respectively
    		                 695,000                                                        
      liabilities and stockholders' equity
    		                                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 101,408 and 101,392 issued and outstanding as of march 31, 2021 and december 31, 2020, respectively
    		                  1,014,000                                                       
      equity and other long-term investments
    		                                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 101,392 and 101,288 issued and outstanding as of december 31, 2020 and december 31, 2019, respectively
    		                   1,014,000                                                      
      accumulated other comprehensive income
    		                     -2,000 33,000 27,000 25,000 33,000 10,000       8,000 6,000  11,000    3,706,000 171,000 202,000  92,000 116,000   16,000  28,000 77,000   61,000 198,000 327,000   362,000 81,000 34,000 81,000 26,000          
      equity investments
    		                                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 101,391 and 101,288 issued and outstanding as of september 30, 2020 and december 31, 2019, respectively
    		                    1,014,000                                                     
      common stock: 0.01 par value, 200,000 shares authorized, 101,392 and 101,288 issued and outstanding as of june 30, 2020 and december 31, 2019, respectively
    		                     1,015,000                                                    
      common stock: 0.01 par value, 200,000 shares authorized, 101,320 and 101,288 issued and outstanding as of march 31, 2020 and december 31, 2019, respectively
    		                      1,013,000                                                   
      common stock: 0.01 par value, 200,000 shares authorized, 101,288 and 101,098 issued and outstanding as of december 31, 2019 and 2018, respectively
    		                       1,013,000                                                  
      common stock: 0.01 par value, 200,000 shares authorized, 101,279 and 101,098 issued and outstanding as of september 30, 2019 and december 31, 2018, respectively
    		                        1,013,000                                                 
      operating lease right-of-use asset
    		                          1,421,000                                               
      operating lease liability, current portion
    		                          308,000                                               
      operating lease liability, net of current portion
    		                          1,238,000                                               
      common stock: 0.01 par value, 200,000 shares authorized, 101,272 and 101,098 issued and outstanding as of june 30, 2019 and december 31, 2018, respectively
    		                         1,013,000                                                
      common stock: 0.01 par value, 200,000 shares authorized, 101,183 and 101,098 issued and outstanding as of march 31, 2019 and december 31, 2018, respectively
    		                          1,012,000                                               
      liabilities and stockholders’ deficit
    		                                                                         
      current portion of long-term debt
    		                              25,000,000                                           
      long-term debt, net of current portion, discount and issuance costs
    		                           381,002,000 486,527,000 484,591,000 578,449,000                                           
      stockholders’ deficit:
    		                                                                         
      common stock: 0.01 par value, 200,000 shares authorized, 101,189 and 102,046 shares issued as of september 30, 2018 and december 31, 2017, respectively
    		                           1,011,000                                              
      accumulated other comprehensive loss
    		                                                                         
      total innoviva stockholders’ deficit
    		                                                                         
      total stockholders’ deficit
    		                                                                         
      total liabilities and stockholders’ deficit
    		                           277,693,000 338,692,000 276,745,000 390,972,000 372,023,000 391,872,000 370,542,000 378,109,000 387,829,000 437,631,000 462,086,000 488,699,000                                   
      royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of 3,456 in the three months ended september 30, 2018 and 2017 and 10,368 in the nine months ended september 30, 2018 and 2017
    		                           61,680,000                                              
      revenue from collaborative arrangements from a related party
    		                              221,000 221,000 221,000 221,000 221,000 221,000 221,000 221,000 222,000                                   
      total net revenue
    		                           61,680,000 67,086,000 52,380,000 48,643,000 58,562,000 40,492,000 33,309,000 32,472,000 24,176,000 13,562,000 10,655,000 6,896,000                                   
      operating expenses:
    		                                                                         
      research and development
    		                              311,000 348,000 354,000 286,000 370,000 392,000 547,000 638,000 712,000          27,837,000 22,798,000 20,464,000 18,537,000 18,705,000 20,351,000 19,541,000 20,020,000 19,557,000                 
      general and administrative
    		                           4,019,000 4,411,000 8,985,000 8,310,000 10,384,000 10,795,000 5,105,000 6,225,000 6,252,000 4,581,000 4,909,000 5,439,000          7,796,000 7,248,000 7,169,000 6,610,000 6,991,000 6,476,000 7,061,000 6,796,000 7,052,000                 
      general and administrative - related party
    		                             2,700,000                                            
      total operating expenses
    		                           4,019,000 4,411,000 11,685,000 8,621,000 10,732,000 11,149,000 5,391,000 6,595,000 6,644,000 5,128,000 5,547,000 6,151,000          35,633,000 30,046,000 27,633,000 25,147,000 25,696,000 26,827,000 26,596,000 26,846,000 27,892,000                 
      income from operations
    		                           57,661,000 62,675,000 40,695,000 40,022,000 47,830,000 29,343,000 27,918,000 25,877,000 17,532,000 8,434,000 5,108,000 745,000                                   
      other income
    		                            39,000    47,000 56,000 1,719,000    1,178,000                                   
      interest income
    		                           370,000 380,000 391,000 376,000 306,000 236,000 162,000 157,000 92,000 90,000 85,000 116,000          81,000 118,000 145,000                       
      interest expense
    		                                                                         
      net income
    		                           50,167,000 56,616,000 30,330,000 23,767,000 35,146,000 16,845,000 15,033,000 14,597,000 4,435,000 -4,584,000 -7,810,000 -10,667,000          -30,626,000 -25,045,000 -22,667,000 -21,222,000 -20,806,000 -22,536,000 -22,183,000 -21,692,000 -19,217,000                 
      net income attributable to noncontrolling interest
    		                           3,078,000 1,990,000 749,000                                            
      net income attributable to innoviva stockholders
    		                           47,089,000 54,626,000 29,581,000                                            
      basic net income per share attributable to innoviva stockholders
    		                           470 540 290                                            
      diluted net income per share attributable to innoviva stockholders
    		                           430 490 270                                            
      shares used to compute innoviva basic and diluted net income per share:
    		                                                                         
      shares used to compute basic net income per share
    		                           100,936,000 100,873,000 100,604,000 106,841,000 107,614,000 107,487,000 109,282,000 111,359,000 112,482,000                                      
      shares used to compute diluted net income per share
    		                           113,363,000 113,399,000 113,566,000 119,796,000 120,463,000 120,336,000 121,993,000 124,316,000 113,178,000                                      
      common stock: 0.01 par value, 200,000 shares authorized, 101,657 and 102,046 shares issued as of june 30, 2018 and december 31, 2017, respectively
    		                            1,015,000                                             
      royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of 3,456 in the three months ended june 30, 2018 and 2017 and 6,912 in the six months ended june 30, 2018 and 2017
    		                            67,086,000                                             
      common stock: 0.01 par value, 200,000 shares authorized, 101,475 and 102,046 shares issued as of march 31, 2018 and december 31, 2017, respectively
    		                             1,014,000                                            
      royalty revenue from a related party, net of amortization of capitalized fees paid to a related party of 3,456 in the three months ended march 31, 2018 and 2017
    		                             52,380,000                                            
      deferred revenue, current
    		                              885,000 885,000 885,000         8,814,000 9,601,000 8,974,000 9,881,000 4,945,000 5,771,000 5,771,000 20,887,000 20,553,000 21,238,000                       
      common stock: 0.01 par value, 200,000 shares authorized, 108,152 and 108,585 shares issued as of september 30, 2017 and december 31, 2016, respectively
    		                              1,080,000                                           
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended september 30, 2017 and 2016 and 10,368 for the nine months ended september 30, 2017 and 2016
    		                              48,422,000                                           
      basic net income per share
    		                              220 330 160                                         
      diluted net income per share
    		                              210 300 150                                         
      shares used to compute basic and diluted net income per share:
    		                                                                         
      non-recourse notes, due 2029, current
    		                               15,181,000 6,703,000 3,551,000 3,266,000                                       
      convertible subordinated notes, due 2023, net of issuance costs
    		                               237,858,000 237,724,000 241,535,000 241,408,000                                       
      non-recourse notes, due 2029, net of issuance costs
    		                               400,854,000 464,601,000 477,914,000 480,879,000                                       
      common stock: 0.01 par value, 200,000 shares authorized, 109,510 and 108,585 shares issued as of june 30, 2017 and december 31, 2016, respectively
    		                               1,094,000                                          
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended june 30, 2017 and 2016 and 6,912 for the six months ended june 30, 2017 and 2016
    		                               58,341,000                                          
      common stock: 0.01 par value, 200,000 shares authorized, 109,348 and 108,585 shares issued as of march 31, 2017 and december 31, 2016, respectively
    		                                1,093,000                                         
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended march 31, 2017 and 2016
    		                                40,271,000                                         
      common stock: 0.01 par value, 200,000 shares authorized, 109,690 and 114,933 shares issued as of september 30, 2016 and december 31, 2015, respectively
    		                                 1,098,000                                        
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 3,455 for the three months ended september 30, 2016 and 2015 and 10,368 and 10,367 for the nine months ended september 30, 2016 and 2015
    		                                 33,088,000                                        
      basic net income per share:
    		                                 140                                        
      diluted net income per share:
    		                                 130                                        
      cash dividends declared per common share
    		                                      250                                   
      common stock: 0.01 par value, 200,000 shares authorized, 111,617 and 114,933 shares issued as of june 30, 2016 and december 31, 2015, respectively
    		                                  1,116,000                                       
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 3,456 for the three months ended june 30, 2016 and 2015 and 6,912 and 6,912 for the six months ended june 30, 2016 and 2015
    		                                  32,251,000                                       
      basic and diluted net income per share
    		                                  130 40 -40 -70           -370 -310 -280 -290 -280 -350 -350 -350 -310                 
      cash dividend declared per common share
    		                                    250 250                                    
      convertible subordinated notes, due 2023
    		                                   251,124,000 255,109,000 255,109,000 255,109,000                                   
      non-recourse notes, due 2029
    		                                   483,389,000 488,976,000 483,363,000 476,954,000                                   
      common stock: 0.01 par value, 200,000 shares authorized, 113,146 and 114,933 shares issued as of march 31, 2016 and december 31, 2015, respectively
    		                                   1,132,000                                      
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 for the three months ended march 31, 2016 and 2015
    		                                   23,955,000                                      
      marketable securities
    		                                      3,932,000 47,752,000 34,349,000 59,831,000 88,333,000 90,314,000 99,342,000   185,854,000 202,433,000 193,229,000 145,945,000 129,367,000 140,972,000 115,525,000 88,640,000 114,585,000 105,958,000 89,871,000 144,737,000 176,384,000 58,678,000 105,107,000 107,482,000 128,692,000 137,525,000 157,543,000 155,073,000 112,138,000 149,964,000 138,499,000 146,333,000 155,730,000 136,334,000 
      payable to theravance biopharma, inc.
    		                                     150,000 126,000  15,243,000                                 
      deferred rent
    		                                    100,000 102,000 89,000 54,000 13,000 4,891,000 4,658,000 4,698,000 4,872,000 5,275,000 5,477,000 5,678,000    2,488,000 1,782,000 709,000 1,121,000 1,280,000 1,440,000 1,680,000 1,801,000 1,921,000 2,085,000 2,149,000 2,225,000 2,298,000 2,572,000 2,573,000 2,573,000 2,538,000 2,669,000 2,569,000 2,534,000 2,500,000 2,336,000 
      common stock: 0.01 par value, 200,000 shares authorized, 117,575 and 116,445 shares issued as of september 30, 2015 and december 31, 2014, respectively
    		                                    1,176,000                                     
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,455 and 3,233 for the three months ended september 30, 2015 and 2014 and 10,367 and 7,611 for the nine months ended september 30, 2015 and 2014
    		                                    13,341,000                                     
      income from continuing operations before income taxes
    		                                                                         
      income tax benefit
    		                                                                         
      income from continuing operations, net of tax
    		                                                                         
      income from discontinued operations
    		                                                                         
      basic and diluted net income per share:
    		                                                                         
      continuing operations, net of tax
    		                                    -40 -70                                    
      discontinued operations
    		                                                                         
      shares used to compute basic and diluted net income per share
    		                                    115,787,000 115,329,000 114,658,000                                   
      common stock: 0.01 par value, 200,000 shares authorized, 117,174 and 116,445 shares issued as of june 30, 2015 and december 31, 2014, respectively
    		                                     1,172,000                                    
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 2,598 for the three months ended june 30, 2015 and 2014 and 6,912 and 4,378 for the six months ended june 30, 2015 and 2014
    		                                     10,434,000                                    
      income tax expense
    		                                                                         
      captialized fees paid to a related party
    		                                      204,735,000                                   
      common stock: 0.01 par value, 200,000 shares authorized, 116,920 and 116,445 shares issued as of march 31, 2015 and december 31, 2014, respectively
    		                                      1,169,000                                   
      royalty revenue from a related party, net of amortization for capitalized fees paid to a related party of 3,456 and 1,780 for the three months ended march 31, 2015 and 2014
    		                                      6,674,000                                   
      income from continuing operations
    		                                                                         
      continuing operations
    		                                      -90                                   
      restricted cash
    		                                       5,600,000 14,232,000 833,000 833,000 833,000 833,000 833,000 833,000 893,000 893,000 893,000 893,000 893,000 893,000 1,310,000 1,310,000 1,310,000 3,810,000 3,810,000 3,810,000 3,810,000              
      receivables from collaborative arrangements
    		                                       4,012,000 3,473,000 865,000 2,489,000 2,233,000                              
      inventories
    		                                         11,014,000 9,038,000 8,240,000 8,049,000                             
      liabilities and stockholders’ (deficit) equity
    		                                                                         
      payable to a related party
    		                                       10,000,000 15,000,000                                 
      accrued clinical and development expenses
    		                                         9,890,000 10,599,000 9,222,000 6,054,000 6,761,000 4,898,000 6,547,000 5,075,000 2,850,000 2,759,000 2,553,000 2,231,000 2,449,000 2,585,000 2,917,000 2,775,000 4,881,000 6,618,000 8,440,000 14,952,000 17,901,000 23,083,000 13,608,000 15,593,000 15,353,000 17,043,000 13,779,000 9,769,000 7,648,000 5,716,000 5,579,000 4,907,000 
      convertible subordinated notes
    		                                       255,109,000 287,500,000 287,500,000 287,500,000 459,960,000 460,000,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000 172,500,000              
      non-recourse notes payable, due 2029
    		                                       450,000,000 450,000,000                                 
      stockholders’ (deficit) equity:
    		                                                                         
      common stock
    		                                       1,154,000 1,133,000 1,125,000 1,105,000 1,008,000 993,000 979,000 969,000 865,000 851,000 754,000 722,000 645,000 642,000 637,000 542,000 538,000 533,000 523,000 520,000 516,000 514,000 512,000 508,000 507,000 505,000 503,000 500,000 444,000 442,000 440,000 437,000 435,000 364,000 
      total stockholders’ (deficit) equity
    		                                                                         
      total liabilities and stockholders’ (deficit) equity
    		                                       553,713,000                                  
      short-term investments
    		                                        126,424,000 245,648,000 334,261,000 243,768,000 192,986,000 161,209,000 134,393,000                           
      stockholders’ equity
    		                                                                         
      accrued interest on convertible subordinated notes
    		                                         1,273,000 1,273,000 4,912,000 2,198,000 1,078,000 2,372,000 1,078,000 1,078,000 2,372,000 1,078,000                       
      notes receivable
    		                                          140,000      85,000 200,000 370,000 532,000 434,000 448,000 224,000 227,000 179,000 311,000 503,000 583,000 437,000 365,000 17,000 1,118,000 2,924,000 2,973,000 2,883,000 2,496,000 2,592,000 2,609,000 2,542,000 2,989,000 2,994,000 
      deferred revenue, non-current
    		                                          5,148,000 5,753,000 5,672,000 5,790,000 6,413,000 7,843,000 124,435,000                         
      notes receivable, current
    		                                           140,000   100,000 200,000                          
      intangible asset
    		                                           30,000,000                              
      other assets, non-current
    		                                           7,372,000 7,682,000 1,894,000 2,101,000 2,308,000                          
      notes receivable, non-current
    		                                            140,000 140,000 240,000 140,000                          
      receivable from related party
    		                                             71,000 94,000 63,000    184,000 33,000 16,000 144,000 248,000 269,000 231,000 10,030,000 167,000 98,000 228,000 229,000 608,000 272,000 417,000 4,032,000 990,000 953,000 6,287,000 1,548,000 2,124,000 1,527,000 
      note receivable, current
    		                                             100,000                            
      prepaid and other current assets
    		                                             3,772,000 3,398,000 3,900,000    4,303,000 5,063,000 6,237,000 8,273,000 8,315,000 10,576,000 8,348,000 9,611,000 9,963,000 6,363,000 5,681,000 5,805,000 4,361,000 3,858,000 4,471,000 4,051,000 3,903,000 3,735,000 4,583,000 5,126,000 5,203,000 6,426,000 
      long-term marketable securities
    		                                             88,962,000 83,208,000                           
      note payable and capital lease
    		                                                                         
      accrued personnel related expenses
    		                                              5,669,000 4,884,000                          
      note payable and capital lease, current
    		                                               13,000 109,000 162,000 200,000                       
      accounts receivable from related party
    		                                                63,000 32,000 332,000                       
      liabilities and stockholders’ net capital deficiency
    		                                                                         
      other current liabilities
    		                                                1,843,000 1,935,000 1,724,000                       
      deferred rent, non-current
    		                                                5,728,000 5,518,000 4,586,000                       
      note payable and capital lease, non-current
    		                                                                         
      stockholders’ net capital deficiency:
    		                                                                         
      class a common stock
    		                                                 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 94,000 90,000 
      total stockholders’ net capital deficiency
    		                                                                         
      total liabilities and stockholders’ net capital deficiency
    		                                                283,325,000 303,120,000 315,108,000 212,580,000 232,449,000 249,930,000 183,472,000 206,085,000 214,792,000                 
      revenue
    		                                                6,431,000 6,389,000 6,331,000 5,302,000 6,264,000 5,714,000 5,515,000 5,493,000 9,544,000                 
      shares used in computing basic and diluted net income per share
    		                                                82,490,000 81,811,000 80,854,000   64,921,000 63,236,000                   
      accrued personnel -related expenses
    		                                                  4,206,000                       
      notes payable and capital lease, non-current
    		                                                  13,000                       
      other long-term assets
    		                                                   3,547,000 3,754,000 3,960,000 4,374,000 4,580,000 4,787,000 5,201,000 5,407,000               
      current portion of note payable and capital lease
    		                                                   202,000 195,000 191,000 181,000 175,000                  
      current portion of deferred revenue
    		                                                   22,802,000 22,802,000 22,801,000 22,061,000 22,026,000 21,223,000 23,996,000 23,996,000 22,589,000 22,740,000 21,221,000 21,221,000 19,273,000 22,032,000 21,452,000 17,480,000 16,994,000 12,021,000 12,021,000 11,563,000 10,959,000 10,959,000 
      notes payable and capital lease
    		                                                   109,000 175,000 213,000 311,000 359,000                  
      restructuring charges
    		                                                       30,000 1,283,000                 
      interest and other income
    		                                                   136,000 134,000 94,000 413,000 1,172,000 647,000                 
      shares used in computing net income per share
    		                                                   73,726,000 73,282,000   62,842,000 62,288,000                 
      preferred stock, 0.01 par value, 230 shares authorized, no shares issued and outstanding
    		                                                                         
      current portion of note payable
    		                                                        121,000 113,000 109,000 105,000              
      notes payable
    		                                                        286,000 349,000 379,000 408,000 462,000 488,000 513,000 538,000 570,000 589,000 607,000 631,000 656,000 669,000 688,000 706,000 723,000 
      other long term assets
    		                                                           5,614,000              
      other long term liabilities
    		                                                           4,139,000 8,281,000 7,632,000 2,653,000 2,286,000 3,818,000 3,421,000 3,055,000 2,658,000      
      restricted cash and cash equivalents
    		                                                            3,810,000 3,830,000 3,830,000 3,860,000 3,860,000 3,860,000 3,860,000 3,860,000 3,860,000 3,860,000 4,194,000 4,537,000 4,923,000 
      current portion of notes payable
    		                                                            98,000 94,000 91,000 87,000 75,000 75,000 75,000 75,000 67,000 70,000 167,000 262,000 354,000 
      notes receivable from stockholders
    		                                                                         
      deferred sublease costs
    		                                                                   297,000 357,000 416,000 476,000 545,000 614,000 
      current portion of capital lease obligations
    		                                                                464,000 598,000 927,000 1,169,000 995,000 1,087,000 1,442,000 2,359,000 2,916,000 
      deferred stock-based compensation
    		                                                                         
      preferred stock, 0.01 par value; 230 shares authorized, no shares issued and outstanding
    		                                                                         
      deferred sublease cost
    		                                                                 178,000 238,000       
      notes receivable from related parties
    		                                                                     7,000 52,000 64,000 75,000 
      capital lease obligations
    		                                                                    458,000 668,000 905,000 1,073,000 1,427,000 
      liabilities, convertible preferred stock and stockholders’ equity
    		                                                                         
      convertible preferred stock, 0.01 par value; no shares authorized, issued or outstanding at december 31, 2004; 50,000 shares authorized and 47,644 shares issued and outstanding at december 31, 2003, aggregate liquidation preference of 374,468 at december 31, 2003.
    		                                                                         
      total liabilities, convertible preferred stock, and stockholders’ equity
    		                                                                       286,022,000 204,974,000 
      commitments
    		                                                                         
      convertible preferred stock, 0.01 par value; 50,000 shares authorized; no shares outstanding at september 30, 2004;47,644 shares issued and outstanding at december 31, 2003, aggregate liquidation preference of 374,468 at december 31, 2003.
    		                                                                         
      preferred stock, 0.01 par value, 5,000 shares authorized, no shares issued and outstanding
    		                                                                         
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.